Preclinical evaluation of the novel [
HD
Mouse
Proteinopathy
mHTT aggregates
zQ175DN
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
received:
22
05
2024
accepted:
10
08
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
Positron emission tomography (PET) imaging of mutant huntingtin (mHTT) aggregates is a potential tool to monitor disease progression as well as the efficacy of candidate therapeutic interventions for Huntington's disease (HD). To date, the focus has been mainly on the investigation of After characterising [ Plasma and brain radiometabolite profiles indicated a suitable metabolic profile for in vivo imaging of [ Overall, [
Identifiants
pubmed: 39190197
doi: 10.1007/s00259-024-06880-x
pii: 10.1007/s00259-024-06880-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CHDI Foundation
ID : A-11627
Organisme : Research Foundation Flanders
ID : 1229721N
Organisme : Universiteit Antwerpen
ID : FFB210050
Informations de copyright
© 2024. The Author(s).
Références
Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89:910–26. https://doi.org/10.1016/j.neuron.2016.02.003 .
doi: 10.1016/j.neuron.2016.02.003
pubmed: 26938440
The-Huntington’s-Disease-Collaborative-Research-Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–83. https://doi.org/10.1016/0092-8674(93)90585-e .
doi: 10.1016/0092-8674(93)90585-e
Waldvogel HJ, Kim EH, Tippett LJ, Vonsattel JP, Faull RL. The neuropathology of huntington’s disease. Curr Top Behav Neurosci. 2015;22:33–80. https://doi.org/10.1007/7854_2014_354 .
doi: 10.1007/7854_2014_354
pubmed: 25300927
Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in huntington’s disease. Neuron. 2019;101:801–19. https://doi.org/10.1016/j.neuron.2019.01.039 .
doi: 10.1016/j.neuron.2019.01.039
pubmed: 30844400
Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 2017;16:837–47. https://doi.org/10.1016/s1474-4422(17)30280-6 .
doi: 10.1016/s1474-4422(17)30280-6
pubmed: 28920889
pmcid: 5604739
Hensman Moss DJ, Robertson N, Farmer R, Scahill RI, Haider S, Tessari MA, et al. Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays. PLoS ONE. 2017;12:e0189891. https://doi.org/10.1371/journal.pone.0189891 .
doi: 10.1371/journal.pone.0189891
pubmed: 29272284
pmcid: 5741241
Macdonald D, Tessari MA, Boogaard I, Smith M, Pulli K, Szynol A, et al. Quantification assays for total and polyglutamine-expanded huntingtin proteins. PLoS ONE. 2014;9:e96854. https://doi.org/10.1371/journal.pone.0096854 .
doi: 10.1371/journal.pone.0096854
pubmed: 24816435
pmcid: 4016121
Reindl W, Baldo B, Schulz J, Janack I, Lindner I, Kleinschmidt M, et al. Meso scale discovery-based assays for the detection of aggregated huntingtin. PLoS ONE. 2019;14:e0213521. https://doi.org/10.1371/journal.pone.0213521 .
doi: 10.1371/journal.pone.0213521
pubmed: 30913220
pmcid: 6435127
Liu L, Prime ME, Lee MR, Khetarpal V, Brown CJ, Johnson PD, et al. Imaging mutant huntingtin aggregates: development of a potential PET ligand. J Med Chem. 2020;63:8608–33. https://doi.org/10.1021/acs.jmedchem.0c00955 .
doi: 10.1021/acs.jmedchem.0c00955
pubmed: 32662649
Liu L, Johnson PD, Prime ME, Khetarpal V, Lee MR, Brown CJ, et al. [(11)C]CHDI-626, a PET tracer candidate for imaging mutant huntingtin aggregates with reduced binding to AD pathological proteins. J Med Chem. 2021;64:12003–21. https://doi.org/10.1021/acs.jmedchem.1c00667 .
doi: 10.1021/acs.jmedchem.1c00667
pubmed: 34351166
Herrmann F, Hessmann M, Schaertl S, Berg-Rosseburg K, Brown CJ, Bursow G, et al. Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates. Sci Rep. 2021;11:17977. https://doi.org/10.1038/s41598-021-97334-z .
doi: 10.1038/s41598-021-97334-z
pubmed: 34504195
pmcid: 8429736
Bertoglio D, Verhaeghe J, Miranda A, Wyffels L, Stroobants S, Mrzljak L, et al. Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease. Eur J Nucl Med Mol Imaging. 2022;49:1166–75. https://doi.org/10.1007/s00259-021-05578-8 .
doi: 10.1007/s00259-021-05578-8
pubmed: 34651228
Bertoglio D, Bard J, Hessmann M, Liu L, Gartner A, De Lombaerde S, et al. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s disease. Sci Transl Med. 2022;14:eabm3682. https://doi.org/10.1126/scitranslmed.abm3682 .
doi: 10.1126/scitranslmed.abm3682
pubmed: 35108063
Bertoglio D, Weiss AR, Liguore W, Martin LD, Hobbs T, Templon J, et al. In vivo cerebral imaging of mutant huntingtin aggregates using (11)C-CHDI-180R PET in a nonhuman primate model of huntington disease. J Nucl Med. 2023. https://doi.org/10.2967/jnumed.123.265569 .
doi: 10.2967/jnumed.123.265569
pubmed: 37591545
pmcid: 10586486
Burns HD, Hamill TG, Eng W-S, Hargreaves R. Annual Reports In Medicinal Chemistry - Section VI - Topics in Drug Design and Discovery. United States of America: Academic Press; 2001.
Li S, Schmitz A, Lee H, Mach RH. Automation of the Radiosynthesis of Six Different (18)F-labeled radiotracers on the AllinOne. EJNMMI Radiopharm Chem. 2017;1:15. https://doi.org/10.1186/s41181-016-0018-0 .
doi: 10.1186/s41181-016-0018-0
pubmed: 29564391
Liu L, Johnson PD, Prime ME, Khetarpal V, Brown CJ, Anzillotti L, et al. Design and evaluation of [(18)F]CHDI-650 as a positron emission tomography ligand to image mutant huntingtin aggregates. J Med Chem. 2022. https://doi.org/10.1021/acs.jmedchem.2c01585 .
doi: 10.1021/acs.jmedchem.2c01585
pubmed: 36584344
pmcid: 11167723
Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS ONE. 2012;7:e49838. https://doi.org/10.1371/journal.pone.0049838 .
doi: 10.1371/journal.pone.0049838
pubmed: 23284626
pmcid: 3527464
Heikkinen T, Lehtimaki K, Vartiainen N, Puolivali J, Hendricks SJ, Glaser JR, et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS ONE. 2012;7:e50717. https://doi.org/10.1371/journal.pone.0050717 .
doi: 10.1371/journal.pone.0050717
pubmed: 23284644
pmcid: 3527436
Cudalbu C, McLin VA, Lei H, Duarte JM, Rougemont AL, Oldani G, et al. The C57BL/6J mouse exhibits sporadic congenital portosystemic shunts. PLoS ONE. 2013;8:e69782. https://doi.org/10.1371/journal.pone.0069782 .
doi: 10.1371/journal.pone.0069782
pubmed: 23936100
pmcid: 3720623
Bertoglio D, Verhaeghe J, Korat S, Miranda A, Wyffels L, Stroobants S, et al. In vitro and in vivo assessment of suitable reference region and kinetic modelling for the mGluR1 radioligand [(11)C]ITDM in Mice. Mol Imaging Biol. 2020;22:854–63. https://doi.org/10.1007/s11307-019-01435-1 .
doi: 10.1007/s11307-019-01435-1
pubmed: 31792838
Bertoglio D, Verhaeghe J, Miranda A, Kertesz I, Cybulska K, Korat S, et al. Validation and noninvasive kinetic modeling of [(11)C]UCB-J PET imaging in mice. J Cereb Blood Flow Metab. 2020;40:1351–62. https://doi.org/10.1177/0271678X19864081 .
doi: 10.1177/0271678X19864081
pubmed: 31307287
Verhaeghe J, Bertoglio D, Kosten L, Thomae D, Verhoye M, Van Der Linden A, et al. Noninvasive relative quantification of [(11)C]ABP688 PET imaging in mice versus an input function measured over an arteriovenous shunt. Front Neurol. 2018;9:516. https://doi.org/10.3389/fneur.2018.00516 .
doi: 10.3389/fneur.2018.00516
pubmed: 30013509
pmcid: 6036254
Miranda A, Bertoglio D, Glorie D, Stroobants S, Staelens S, Verhaeghe J. Validation of a spatially variant resolution model for small animal brain PET studies. Biomed Phys Eng Express. 2020;6:045001. https://doi.org/10.1088/2057-1976/ab8c13 .
doi: 10.1088/2057-1976/ab8c13
pubmed: 33444262
Bertoglio D, Verhaeghe J, Kosten L, Thomae D, Van der Linden A, Stroobants S, et al. MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington’s disease. PLoS ONE. 2018;13:e0206613. https://doi.org/10.1371/journal.pone.0206613 .
doi: 10.1371/journal.pone.0206613
pubmed: 30365550
pmcid: 6203386
Johnson GA, Badea A, Brandenburg J, Cofer G, Fubara B, Liu S, et al. Waxholm space: an image-based reference for coordinating mouse brain research. Neuroimage. 2010;53:365–72. https://doi.org/10.1016/j.neuroimage.2010.06.067 .
doi: 10.1016/j.neuroimage.2010.06.067
pubmed: 20600960
Cicchetti D. Guidlines, criteria, and rules of thum for evaluating nomred and standardized assessment instruments in psychology. Psychol Assess. 1994;6:284–90. 1040–3590/94/53.00.
Kaur T, Brooks AF, Lapsys A, Desmond TJ, Stauff J, Arteaga J, et al. Synthesis and evaluation of a fluorine-18 radioligand for imaging Huntingtin aggregates by positron emission tomographic imaging. Front Neurosci. 2021;15. https://doi.org/10.3389/fnins.2021.766176 .